A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

• ClinicalTrials.gov Identifier: NCT03468426
• Recruitment Status: Active, not recruiting
• First Posted: March 16, 2018
• Last Update Posted: April 3, 2024
• Sponsor: Boehringer Ingelheim
• Information provided by (Responsible Party): Boehringer Ingelheim

Tracking Information

• First Submitted Date: March 8, 2018
• First Posted Date: March 16, 2018
• Last Update Posted Date: April 3, 2024
• Actual Study Start Date: May 3, 2018
• Estimated Primary Completion Date: August 6, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 27, 2021)

• Part 1: Number of patients with Dose Limiting Toxicities (DLTs) within the first cycle of treatment [ Time Frame: Up to 3 weeks ]
• Part 2: Objective response [ Time Frame: Up to 3 years ]

Original Primary Outcome Measures (submitted: March 15, 2018)

• PART 1: Number of patients with Dose Limiting Toxicities (DLTs) within the first cycle of treatment [ Time Frame: Up to 3 weeks ]
• PART 2: Objective Response (OR) [ Time Frame: Up to 3 years ]

Current Secondary Outcome Measures (submitted: August 27, 2021)

• Part 1: Adverse events (AEs), drug related AEs, drug related AEs leading to discontinuation during treatment period [ Time Frame: Up to 294 days ]
• Part 1: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours (AUC 0-504h) after the first infusion cycle [ Time Frame: Up to 504 hours after first infusion cycle ]
• Part 1: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours (AUC 0-504h) after the fourth infusion cycle [ Time Frame: Up to 504 hours after fourth infusion cycle ]
• Part 1: Maximum measured concentration of the analyte in plasma (Cmax) [ Time Frame: Up to 12 weeks ]
• Part 1: Time from dosing to maximum measured concentration of the analyte in plasma (tmax) [ Time Frame: Up to 12 weeks ]
• Part 2: Adverse events (AEs), drug related AEs, drug related AEs leading to discontinuation during treatment period [ Time Frame: Up to 294 days ]
• Part 2: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours (AUC 0-504h) after the first infusion cycle [ Time Frame: Up to 504 hours after first infusion cycle ]
• Part 2: Time from dosing to maximum measured concentration of the analyte in plasma (tmax) [ Time Frame: Up to 12 weeks ]
• Part 2: Maximum measured concentration of the analyte in plasma (Cmax) [ Time Frame: Up to 12 weeks ]
• Part 2: Disease control (DC) [ Time Frame: Up to 3 years ]
• PART 2: Duration of objective response (DoR) [ Time Frame: Up to 3 years ]
• Part 2: Progression-free survival (PFS) [ Time Frame: Up to 3 years ]
• Part 2: Tumour shrinkage (in millimeters) [ Time Frame: Up to 3 years ]

Original Secondary Outcome Measures (submitted: March 15, 2018)

• PART 1:Adverse events (AEs), drug related AEs, drug related AEs leading to dose reduction or discontinuation during treatment period [ Time Frame: Up to 3 weeks ]
• PART 1: AUC 0-504h (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours after the first and fourth infusion cycle) [ Time Frame: Up to 504 hours after first and fourth infusion cycle ]
• PART 2:Adverse events (AEs), drug related AEs, drug related AEs leading to dose reduction or discontinuation during treatment period [ Time Frame: Up to 3 weeks ]
• PART 2: Disease control (DC) [ Time Frame: Up to 3 years ]
• PART 2: Duration of objective response (DoR) [ Time Frame: Up to 3 years ]
• PART 2: Progression-free survival (PFS) [ Time Frame: Up to 3 years ]
• PART 2: Tumour shrinkage (in millimeters) [ Time Frame: Up to 3 years ]
• PART 2: AUC 0-504h (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours after the first and fourth infusion cycle) [ Time Frame: Up to 504 hours after first and fourth infusion cycle ]
• PART 1: Cmax (maximum measured concentration of the analyte in plasma) [ Time Frame: Up to 12 weeks ]
• PART 1: tmax (time from dosing to maximum measured concentration of the analyte in plasma) [ Time Frame: Up to 12 weeks ]
• PART 2: Cmax (maximum measured concentration of the analyte in plasma) [ Time Frame: Up to 12 weeks ]
• PART 2: tmax (time from dosing to maximum measured concentration of the analyte in plasma) [ Time Frame: Up to 12 weeks ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
• Official Title: An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors

Brief Summary

This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver. After early encouraging results, more people with liver cancer can now take part in the study. The participants get a combination of two medicines called BI 836880 and ezabenlimab.

BI 836880 is a type of an antibody that blocks new blood vessel formation. New blood vessels are needed by the tumour to continue growing. Ezabenlimab is an antibody that may help the immune system fight cancer (immune checkpoint inhibitor).

The purpose of the first part of the study was to find out the highest dose of the BI 836880 that the participants can tolerate in combination with BI 754091. After the best dose of BI 836880 for the combination with ezabenlimab was found, it is used in the second part of the study. The purpose of the second part is to see whether the combination of BI 836880 and BI 754091 is able to make tumours shrink.

The participants are in the study as long as they benefit from and can tolerate treatment. During this time, they get infusions of BI 836880 and ezabenlimab every 3 weeks. The doctors also regularly check the general health of the participants.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Non-squamous, Non-Small-Cell Lung Cancer
• Neoplasms

Intervention

• Drug: BI 836880
  intra-venous infusion
• Drug: ezabenlimab
  intra-venous infusion
  Other Name: BI 754091

Study Arms

Experimental: BI 836880 + ezabenlimab

Interventions:

• Drug: BI 836880
• Drug: ezabenlimab

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: January 20, 2022): 252
• Original Estimated Enrollment (submitted: March 15, 2018): 80
• Estimated Study Completion Date: November 1, 2024
• Estimated Primary Completion Date: August 6, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

Part 1:

• Of full age (according to local legislation, usually ≥ 18 years) at screening.
• Pathologically confirmed locally advanced or metastatic non-squamous NSCLC with PDL-1 expression available and >1% by IHC (as defined by the Pembrolizumab companion diagnostic test, determined by appropriate local pathology lab.
• No previous treatment with check-point inhibitor. Or patients with checkpoint inhibitor based treatment as last therapy before entering the trial.
• Documented disease progression or relapse (based on investigator's assessment) during or after completion of at least 2 cycles of platinum-based chemotherapy as first line treatment of Stage IIIB/IV non- squamous NSCLC or for checkpoint inhibitor experienced patients during or after completion of at least 2 cycles of platinum-based chemotherapy and a checkpoint inhibitor treatment (monotherapy or in combination with chemotherapy). This includes patients relapsing within 6 months of completing (neo)adjuvant/curative-intent chemotherapy/CPI or chemoradiotherapy
• At least one target lesion (outside the brain) that can be accurately measured per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 .
• Lesion with a diameter ≥ 2cm assessed by radiologist as suitable for DCE-MRI evaluation (Mandatory in Part 1, optional in Part 2)
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Life expectancy ≥ 3 months after start of the treatment in the opinion of the investigator
• Recovery from all reversible adverse events of previous anti-cancer therapies to baseline or CTCAE grade 1, except for alopecia (any grade), sensory peripheral neuropathy , must be ≤ CTCAE grade 2 or considered not clinically significant.
• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
• Availability and willingness to provide a fresh tumour tissue sample obtained at baseline, and after 2 cycles of treatment
• Adequate organ function defined as all of the following (all screening labs should be performed at local lab within 10 days prior to treatment initiation)
• Male or female patients. Women of childbearing potential (WOCBP)1 and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, starting with the screening visit and through 6 months after the last dose of BI 836880 and BI 754091 treatment, respectively. A list of contraception methods meeting these criteria is provided in the patient information Note: Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours prior to taking study medication during the screening period. At the following visits according to the flowchart a urine and/or serum pregnancy test is required. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the patient to be eligible.

Part 2:

• Of full age (according to local legislation, usually ≥ 18 years) at screening
• At least one measurable target lesion outside the brain (excluding the glioblastoma patients where brain lesions are allowed), that can be accurately measured per RECIST version 1.1 or Response Assessment in Neuro-Oncology (RANO)
• ECOG performance status ≤ 1 (For glioblastoma cohort Karnofsky status is applicable)
• Adequate organ function as all of the following (all screening labs should be performed at local lab within approximately 72 hours prior to treatment initiation)
• Availability and willingness to provide a fresh tumor tissue sample obtained after relapse or progression on or after prior therapy. For Part 2, In case a fresh biopsy cannot be obtained (e.g. inaccessible lesions or patient safety concern), an archived specimen obtained up to 6 months prior to cycle 1, visit 1 (C1V1) may be submitted in case no systemic antineoplastic therapy has been administered between the biopsy and C1V1 (except for cohort D). For cohorts E, F and G, a fresh on-treatment biopsy is mandatory at C3D1, if possible from the same lesion as the pre-treatment biopsy.
• Life expectancy ≥ 3 months after start of the treatment in the opinion of the investigator
• Recovery from all reversible adverse events of previous anti-cancer therapies to baseline or CTCAE grade 1, except for alopecia (any grade), sensory peripheral neuropathy , must be ≤ CTCAE grade 2 or considered not clinically significant.
• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
• Male or female patients. Women of childbearing potential (WOCBP)2 and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, for the entire duration of the trial treatment intake and for 6 months after the end of the trial treatment. A list of contraception methods meeting these criteria is provided in the patient information.

Note: Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours during the screening period. At the following visits according to the flowchart, a urine and/or serum pregnancy test is required. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the patient to be eligible.- Further inclusion criteria apply

Exclusion criteria:

Part 1:

• Known hypersensitivity to the trial drugs or their excipients or risk of allergic of anaphylactic reaction to drug product according to Investigator judgement (e.g. patient with history of anaphylactic reaction or autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids, or the equivalent of </= 10 mg/day prednisone).
• Known immunodeficiency virus infection or an active hepatitis B or C virus infection.
• History of severe hypersensitivity reactions to other mAbs.
• Immunosuppressive corticosteroid doses (> 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of trial medication.
• Current or prior treatment with any systemic anti-cancer therapy either within 28 days or a minimum of 5 half-lives, whichever is shorter before start of treatment.
• Serious concomitant disease, especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the endpoints of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
• Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment, or planned surgical procedures during the trial period.
• Patients with personal or family history of QT prolongation and/or long QT syndrome, or prolonged QTcF at baseline (> 480 ms).
• Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure > NYHA II).

Uncontrolled hypertension defined as: Blood pressure in rested and relaxed condition >= 140 mmHg, systolic or >= 90 mmHg diastolic (with or without medication), measured according to Appendix 10.2.

• LVEF < 50%
• History of severe hemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).
• Known inherited predisposition to bleeding or to thrombosis in the opinion of the investigator.
• Patient with brain metastases that are symptomatic and/or require therapy.
• Patients who require full-dose anticoagulation (according to local guidelines). No Vitamin K antagonist and other anticoagulation allowed; LMWH allowed only for prevention not for curative treatment.
• History of pneumonitis within the last 5 years
• Patients who are under judicial protection and patients who are legally institutionalized.
• Patients unable or unwilling to comply with protocol
• Previous enrolment in this trial (Part 1 or Part 2).
• Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial.
• Women who are pregnant, nursing, or who plan to become pregnant in the trial

Part 2:

• Known hypersensitivity to the trial drugs or their excipients or risk of allergic of anaphylactic reaction to drug product according to Investigator judgement (e.g. patient with history of anaphylactic reaction or autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids, or the equivalent of </= 10 mg/day prednisone).
• Not more than one CPI based treatment regimen prior to entering study (e.g. anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody). In case of CPIs combination, they need to be approved by the local regulatory agencies; for e.g., Melanoma cohort (Cohort E).
• Known HIV infection
• Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (exception for patients in HCC cohorts; Cohorts F& G).
• History of severe hypersensitivity reactions to other mAbs.
• Immunosuppressive corticosteroid doses (> 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of trial medication except for control of cerebral edema in case of recurrent glioblastoma (cohort D).
• Current or prior treatment with any systemic anti-cancer therapy (including radiotherapy) either within 28 days or a minimum of 5 half-lives, whichever is shorter before start of treatment
• Serious concomitant disease, especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the endpoints of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
• Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment, or planned surgical procedures during the trial period.
• Patients with personal or family history of QT prolongation and/or long QT syndrome, or prolonged QTcF at baseline (> 480 ms).
• Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure > NYHA II).

Uncontrolled hypertension defined as: Blood pressure in rested and relaxed condition >= 140 mmHg, systolic or >= 90 mmHg diastolic (with or without medication), measured according to Appendix 10.2.

• LVEF < 50%
• History of severe hemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).
• Known inherited predisposition to bleeding or to thrombosis in the opinion of the investigator.
• Patient with brain metastases that are symptomatic and/or require therapy.
• Patients who require full-dose anticoagulation (according to local guidelines).
• No Vitamin K antagonist and other anticoagulation allowed; LMWH allowed only for prevention not for curative treatment.
• History of pneumonitis (non-infectious) within the last 5 years
• Patients who are under judicial protection and patients who are legally institutionalized.
• Patients unable or unwilling to comply with protocol
• Previous enrolment in this trial.
• Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial.
• Women who are pregnant, nursing, or who plan to become pregnant in the trial
• UncontrolledSymptomatic pleural effusion, pericardial effusion, or ascites
• Prior treatment with any antiangiogenic treatment (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL-184, sunitinib, etc) except for sorafenib and lenvatinib in 2nd line HCC cohort (Cohort F)
• Has received a live vaccine within 30 days prior to the first dose of study drug
• Patients with known active second malignancy other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast. Patients are not considered to have a currently active malignancy if they have completed anticancer therapy and have been disease free for greater than 2 years prior to screening
• Further exclusion criteria apply

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, France, Germany, Hong Kong, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom, United States
• Removed Location Countries: Japan

Administrative Information

• NCT Number: NCT03468426
• Other Study ID Numbers: 1336-0011; 2017-001378-41 ( EudraCT Number )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

Plan Description

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:

1. studies in products where Boehringer Ingelheim is not the license holder;
2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).

For more details refer to: https://www.mystudywindow.com/msw/datasharing

• Current Responsible Party: Boehringer Ingelheim
• Original Responsible Party: Same as current
• Current Study Sponsor: Boehringer Ingelheim
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Boehringer Ingelheim
• Verification Date: April 2024